Cargando…

Increased sensitivity to SMAC mimetic LCL161 identified by longitudinal ex vivo pharmacogenomics of recurrent, KRAS mutated rectal cancer liver metastases

Tumor heterogeneity is a primary cause of treatment failure. However, changes in drug sensitivity over time are not well mapped in cancer. Patient-derived organoids (PDOs) may predict clinical drug responses ex vivo and offer an opportunity to evaluate novel treatment strategies in a personalized fa...

Descripción completa

Detalles Bibliográficos
Autores principales:	Kryeziu, Kushtrim, Moosavi, Seyed H., Bergsland, Christian H., Guren, Marianne G., Eide, Peter W., Totland, Max Z., Lassen, Kristoffer, Abildgaard, Andreas, Nesbakken, Arild, Sveen, Anita, Lothe, Ragnhild A.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	BioMed Central 2021
Materias:	Research
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8424985/ https://www.ncbi.nlm.nih.gov/pubmed/34496878 http://dx.doi.org/10.1186/s12967-021-03062-3

Ejemplares similares

Smac mimetics LCL161 and GDC-0152 inhibit osteosarcoma growth and metastasis in mice
por: Shekhar, Tanmay M., et al.
Publicado: (2019)

The SMAC mimetic LCL-161 selectively targets JAK2(V617F) mutant cells
por: Craver, Brianna M., et al.
Publicado: (2020)

The SMAC mimetic, LCL-161, reduces survival in aggressive MYC-driven lymphoma while promoting susceptibility to endotoxic shock
por: West, A C, et al.
Publicado: (2016)

Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2022)

Molecular correlates of sensitivity to PARP inhibition beyond homologous recombination deficiency in pre-clinical models of colorectal cancer point to wild-type TP53 activity
por: Smeby, Jørgen, et al.
Publicado: (2020)

Smac mimetic LCL161 overcomes protective ER stress induced by obatoclax, synergistically causing cell death in multiple myeloma
por: Ramakrishnan, Vijay, et al.
Publicado: (2016)

Corrigendum: Combining the SMAC mimetic LCL161 with Gemcitabine plus Cisplatin therapy inhibits and prevents the emergence of multidrug resistance in cholangiocarcinoma
por: Prasopporn, Sunisa, et al.
Publicado: (2023)

Prognostic, predictive, and pharmacogenomic assessments of CDX2 refine stratification of colorectal cancer
por: Bruun, Jarle, et al.
Publicado: (2018)

Natural Flavonoids Quercetin and Kaempferol Targeting G2/M Cell Cycle-Related Genes and Synergize with Smac Mimetic LCL-161 to Induce Necroptosis in Cholangiocarcinoma Cells
por: Lomphithak, Thanpisit, et al.
Publicado: (2023)

Spatial analysis and CD25-expression identify regulatory T cells as predictors of a poor prognosis in colorectal cancer
por: Bergsland, Christian H., et al.
Publicado: (2022)

Exploratory analyses of consensus molecular subtype-dependent associations of TP53 mutations with immunomodulation and prognosis in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

Sensitization of neuroblastoma for vincristine-induced apoptosis by Smac mimetic LCL161 is attended by G2 cell cycle arrest but is independent of NFκB, RIP1 and TNF-α
por: Langemann, Doerte, et al.
Publicado: (2017)

Smac mimetic LCL161 supports neuroblastoma chemotherapy in a drug class-dependent manner and synergistically interacts with ALK inhibitor TAE684 in cells with ALK mutation F1174L
por: Najem, Safiullah, et al.
Publicado: (2016)

De novo transcriptomic subtyping of colorectal cancer liver metastases in the context of tumor heterogeneity
por: Moosavi, Seyed H., et al.
Publicado: (2021)

The expressed mutational landscape of microsatellite stable colorectal cancers
por: Sveen, Anita, et al.
Publicado: (2021)

E‐cadherin is a robust prognostic biomarker in colorectal cancer and low expression is associated with sensitivity to inhibitors of topoisomerase, aurora, and HSP90 in preclinical models
por: Bruun, Jarle, et al.
Publicado: (2021)

Transcriptional and functional consequences of TP53 splice mutations in colorectal cancer
por: Smeby, Jørgen, et al.
Publicado: (2019)

Transcriptome instability in colorectal cancer identified by exon microarray analyses: Associations with splicing factor expression levels and patient survival
por: Sveen, Anita, et al.
Publicado: (2011)

Alternative splicing expands the prognostic impact of KRAS in microsatellite stable primary colorectal cancer
por: Eilertsen, Ina A., et al.
Publicado: (2018)

Prediction of relapse-free survival according to adjuvant chemotherapy and regulator of chromosome condensation 2 (RCC2) expression in colorectal cancer
por: Bergsland, Christian H, et al.
Publicado: (2020)

Future Therapeutic Directions for Smac-Mimetics
por: Morrish, Emma, et al.
Publicado: (2020)

Metastatic heterogeneity of the consensus molecular subtypes of colorectal cancer
por: Eide, Peter W., et al.
Publicado: (2021)

LCL161 enhances expansion and survival of engineered anti-tumor T cells but is restricted by death signaling
por: Afsahi, Arya, et al.
Publicado: (2023)

New light on Smac mimetics and breast cancer
por: Cornmark, L, et al.
Publicado: (2016)

Hyperosmotic stress enhances cytotoxicity of SMAC mimetics
por: Bittner, Sebastian, et al.
Publicado: (2017)

SMAC Mimetics as Therapeutic Agents in HIV Infection
por: Molyer, Bengisu, et al.
Publicado: (2021)

Reactivation of Smac-mediated apoptosis in chronic lymphocytic leukemia cells: mechanistic studies of Smac mimetic
por: Balakrishnan, Kumudha, et al.
Publicado: (2016)

LCL161 increases paclitaxel-induced apoptosis by degrading cIAP1 and cIAP2 in NSCLC
por: Yang, Chengcheng, et al.
Publicado: (2016)

Redox regulation of Smac mimetic-induced cell death
por: Fulda, Simone
Publicado: (2015)

Smac-mimetics reduce numbers and viability of human osteoclasts
por: Moen, Ingrid Nyhus, et al.
Publicado: (2021)

Re-assessing ZNF331 as a DNA methylation biomarker for colorectal cancer
por: Vedeld, Hege Marie, et al.
Publicado: (2018)

Gene expression profiles of CMS2-epithelial/canonical colorectal cancers are largely driven by DNA copy number gains
por: Berg, Kaja C. G., et al.
Publicado: (2019)

Digital image analysis of multiplex fluorescence IHC in colorectal cancer recognizes the prognostic value of CDX2 and its negative correlation with SOX2
por: Lopes, Nair, et al.
Publicado: (2019)

CMScaller: an R package for consensus molecular subtyping of colorectal cancer pre-clinical models
por: Eide, Peter W., et al.
Publicado: (2017)

Genomic and prognostic heterogeneity among RAS/BRAF (V600E)/TP53 co‐mutated resectable colorectal liver metastases
por: Berg, Kaja C. G., et al.
Publicado: (2021)

The role of SMAC mimetics in regulation of tumor cell death and immunity
por: Emeagi, Perpetua U., et al.
Publicado: (2012)

Regulation of cancer stem-like cell differentiation by Smac mimetics
por: Fulda, Simone
Publicado: (2014)

Targeting triple-negative breast cancers with the Smac-mimetic birinapant
por: Lalaoui, Najoua, et al.
Publicado: (2020)

Potency and Selectivity of SMAC/DIABLO Mimetics in Solid Tumor Therapy
por: Zhao, Xiao-Yun, et al.
Publicado: (2020)

Long noncoding RNA MIR31HG is a bona fide prognostic marker with colorectal cancer cell‐intrinsic properties
por: Eide, Peter W., et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_iv8rsnba9ihcngh1stb2mevd03